Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Shares Issued (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Shares Issued for 7 consecutive years, with $27.7 million as the latest value for Q4 2025.

  • Quarterly Shares Issued rose 108.92% to $27.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $27.7 million through Dec 2025, up 658.62% year-over-year, with the annual reading at $27.7 million for FY2025, 658.62% up from the prior year.
  • Shares Issued hit $27.7 million in Q4 2025 for BridgeBio Pharma, up from -$3.2 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $276.6 million in Q1 2024 to a low of -$311.1 million in Q4 2024.
  • Historically, Shares Issued has averaged $15.7 million across 5 years, with a median of $321000.0 in 2022.
  • Biggest YoY gain for Shares Issued was 143216.06% in 2024; the steepest drop was 31108600.0% in 2024.
  • Year by year, Shares Issued stood at -$10.5 million in 2021, then surged by 146.79% to $4.9 million in 2022, then tumbled by 99.98% to $1000.0 in 2023, then crashed by 31108600.0% to -$311.1 million in 2024, then skyrocketed by 108.92% to $27.7 million in 2025.
  • Business Quant data shows Shares Issued for BBIO at $27.7 million in Q4 2025, -$3.2 million in Q2 2025, and $3.2 million in Q1 2025.